Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6803655 | 1.00 | CA1 (0.32) | CA1CA2CA4KMT2A | |
| SCHEMBL2421576 | 0.89 | FAAH (0.34) | CA1CA2CA4 | |
| SCHEMBL2421570 | 0.89 | FAAH (0.34) | CA1CA2CA4 | |
| SCHEMBL27771224 | 0.88 | FAAH (0.40) | KMT2A | |
| Acetic Acid Methyl Ester SCHEMBL4937513 | 0.88 | THRB (0.31) | — | |
| SCHEMBL120122 | 0.86 | ALDH1A1 (0.39) | — | |
| SCHEMBL1771016 | 0.86 | ALDH1A1 (0.39) | — | |
| SCHEMBL119856 | 0.86 | ALDH1A1 (0.39) | — | |
| SCHEMBL20853080 | 0.86 | ALDH1A1 (0.39) | — | |
| SCHEMBL28779856 | 0.84 | CA1 (0.37) | CA1CA2CA4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4356894-A1 | SUSTAINABLE PRODUCT WITH MALODORS | Beiersdorf AG (DE) | 2024-04-24 | — | — | EP | claimed |
| EP-1894603-B1 | Encapsulation of bulky fragrance molecules | TAKASAGO PERFUMERY CO LTD (JP) | 2014-11-19 | — | — | EP | claimed |
| CN-118076767-A | Method and formulation for producing an optical metal oxide layer | 默克专利有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-4356894-A1 | SUSTAINABLE PRODUCT WITH MALODORS | Beiersdorf AG (DE) | 2024-04-24 | — | — | EP | disclosed |
| WO-2023057401-A1 | METHOD AND FORMULATION FOR PREPARING OPTICAL METAL OXIDE LAYERS | MERCK PATENT GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| CN-113979980-A | Preparation method of high-purity butyrolactone | 安徽华业香料合肥有限公司 | 2022-01-28 | — | — | CN | disclosed |
| WO-2006116872-A1 | METHODS FOR HORMONE PROFILING | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2006-11-09 | — | — | WO | disclosed |
| US-6774126-B2 | Pyrrolo[1,2-b][1,2,4]oxadiazine diones useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION | 2004-08-10 | — | — | US | disclosed |
| US-20040019019-A1 | Pyrrolo[1,2-b][1,2,4]oxadiazine diones useful as nitric oxide synthase inhibitors | PHARMACIA CORPORATION | 2004-01-29 | — | — | US | disclosed |
| US-6552052-B2 | (2S,3Z)-2-amino-5-(6,7,8,9-tetrahydro-3-oxo-3H,5H -(1,2,4)oxadiazolo(4,3-a)azepin-5-yl)-3-pentenoic acid, for example | MONSANTO/G.D. SEARLE | 2003-04-22 | — | — | US | disclosed |
| US-6489323-B1 | INHIBITING NO PRODUCTION FROM L-ARGININE, AS SEEN IN DISEASE STATES SUCH AS ARTHRITIS AND SYSTEMIC HYPOTENSION ASSOCIATED WITH SEPTIC AND/OR TOXIC SHOCK | G.D. SEARLE & CO. | 2002-12-03 | — | — | US | disclosed |
| US-20010044539-A1 | Heterobicyclic and tricyclic nitric oxide synthase inhibitors | HANSEN DONALD W (US) | 2001-11-22 | — | — | US | disclosed |
| EP-1086108-A1 | HETEROBICYCLIC AND TRICYCLIC NITRIC OXIDE SYNTHASE INHIBITORS | G.D. Searle & Co. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999064426-A1 | HETEROBICYCLIC AND TRICYCLIC NITRIC OXIDE SYNTHASE INHIBITORS | G.D. SEARLE & CO. (US) | 1999-12-16 | — | — | WO | disclosed |
| US-4331611-A | Nitrile and uses of same in perfumes, colognes and perfumed articles | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1982-05-25 | — | — | US | disclosed |
| US-4294863-A | Flavoring with mixture of nor-methyl jasmonate and dihydro-nor-methyl jasmonate | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1981-10-13 | — | — | US | disclosed |
| US-4260512-A | DETERGENTS | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 1981-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044539-A1 | Heterobicyclic and tricyclic nitric oxide synthase inhibitors | NOS1, NOS2, NOS3 | CA1 1778/4885CA2 443/4885CA4 2323/4885 |
| US-20040019019-A1 | Pyrrolo[1,2-b][1,2,4]oxadiazine diones useful as nitric oxide synthase inhibitors | NOS1, NOS2, NOS3 | CA1 2180/4885CA2 871/4885CA4 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.